Home > Resources > Whitepapers > Material Issues in the Pharmaceutical Industry

Material Issues in the Pharmaceutical Industry

THE OVERVIEW of materials of construction corrosion failure mechanisms in the article “Corrosion in the Pharmaceutical Industry” in this Volume continues to be a valuable resource for information on this topic. Some trends in the availability and application of materials in this industry, and current issues relative to pharmaceutical equipment construction, warrant closer examination.

Spotlight

High Purity New England

High Purity New England has grown from a small team of three people to a deeply experienced organization that employs over 200 professionals committed to advancing their customers' bioprocessing objectives from discovery to commercial launch. Their insight into the changing needs of the bioprocessing industry led to their state-of-the-art facility being the first in the Northeastern United States to receive ISO 9001:2015 certification for the specific application of design, development, manufacturing, and distribution of single-use assemblies.

OTHER WHITEPAPERS

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

BIOTECHNOLOGY UPDATE

whitePaper | April 24, 2022

The Global Forum on Biotechnology, established in 2010, is one of 15 Global Fora created by OECD Committees. Global Fora are not official OECD bodiesbut are best described as broad.

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

whitePaper | March 22, 2023

If scaling issues strike you as obvious or even boring, you should read “On Being the Right Size,” a 1926 essay by geneticist J.B.S. Haldane. It makes the case that a difference in scale—a seemingly simple matter—may demand subtle changes in form and function.

Recruitment, Retention & Diversity: The Evolution of Patient Engagement in Clinical Trials

whitePaper | January 23, 2023

Recruitment, retention, and diversity are critical elements of clinical trials that, if insufficient, can jeopardize successful trial completion.

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.